
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is expected to generate significant revenue from successful clinical trials such as JEMPERLI and PREDOSTAR, potentially reaching over $390 million in projected annual royalties starting in 2029. With a current projected stock value of $93 per share, ANAB could see further growth due to positive sales expectations and the potential resolution of a dispute with GSK. Additionally, ANAB has promising potential treatments in development for EoE and celiac disease, supported by strong preclinical data and expected to reach a resolution in June 2027. Using risk-adjusted net present value analysis, the updated PT for ANAB is $95.
Bears say
AnaptysBio is heavily dependent on the success of its pipeline, which is still in early stages of development. The company's financials are also heavily reliant on milestone payments and royalties, which are not guaranteed. Competition in the target markets is fierce, with larger and more established players, making it difficult for AnaptysBio to gain significant market share.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares